Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Comment by HomerAndCompanyon Jul 03, 2021 9:38am
248 Views
Post# 33489413

RE:Insider Buying

RE:Insider BuyingLatest insider public market buy: June 22 (no selling since March) by Director Murielle Lortie, establishing a new position with 880 shares bought at $22.75.

Insider buys is recent months are still dwarfed by the selling done by CFO Aaron Davidson this March and December of last year. Any idea why the CFO was selling? 


retiredcf wrote:

Profound Medical Corp. 

On May 20, chief executive officer and chairman of the board Arun Menawat acquired 5,000 shares at an average cost per share of roughly US$18.71 increasing this specific account’s position to 246,988 shares. The cost of this purchase exceeded US$93,000.



<< Previous
Bullboard Posts
Next >>